The Idiopathic Pulmonary Fibrosis (IPF) Treatment Market is experiencing substantial transformation, driven by advancements in therapeutic options, increased disease awareness, and growing investments in research and development. As idiopathic pulmonary fibrosis remains a progressive and fatal interstitial lung disease with limited curative treatments, the market presents...
English